Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Reimburses Gilead's Sovaldi, Harvoni To Aid Access

This article was originally published in PharmAsia News

Executive Summary

With China and Japan moving to cut prices of Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, South Korea has decided to reimburse the products from May. Although not all HCV genotypes will be covered by national health insurance, the move will sharply ease local patients' cost burden amid an outbreak of infections last year.

Advertisement

Related Content

Korea Moves To Halt Reuse Of Disposable Devices Amid HCV Outbreak

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel